To assess the value of risk-stratification based on magnetic resonance imaging (MRI) and prostate-specific antigen density (PSA-D) in reducing unnecessary biopsies without missing Gleason pattern 4 prostate cancer in men on active surveillance (AS).
Objectives
To assess the value of risk-stratification based on magnetic resonance imaging (MRI) and prostate-specific antigen density (PSA-D) in reducing unnecessary biopsies without missing Gleason pattern 4 prostate cancer in men on active surveillance (AS).
Patients and Methods
In all, 210 men on AS with Gleason score 3 + 3 prostate cancer received a first MRI and if indicated [Prostate Imaging Reporting and Data System (PI-RADS) score ≥3] targeted biopsy (TBx) using MRI-transrectal ultrasonography (TRUS) fusion. The MRI was performed 3 months after diagnosis (group A: n = 97), at confirmatory biopsy (group B: n = 39) or at surveillance biopsy after one or more repeat TRUS-guided systematic biopsies (TRUS-Bx) (group C: n = 74). The primary outcome was upgrading to Gleason score ≥3 + 4 prostate cancer based on MRI AE TBx in groups A, B and C. Biopsy outcomes were stratified for the overall PI-RADS score and PSA-D to identify a subgroup of men in whom a biopsy could have been avoided as no Gleason score upgrading was detected.
Results
In all, 134/210 (64%) men had a positive MRI and 51/210 (24%) men had Gleason score upgrading based on MRI- 
Introduction
Active surveillance (AS) is a widely used strategy for low-risk prostate cancer with confirmed oncological safety at longterm follow-up [1, 2] . However, the repeatedly performed TRUS-guided systematic biopsies (TRUS-Bx) during followup are burdening, causing low compliance and in addition can cause infectious complications [3] [4] [5] . Follow-up compliance is essential for the oncological safety of AS, thus strategies are needed to reduce unnecessary biopsies. MRI is increasingly used in men on AS and could help to select those men who need a repeat biopsy. An MRI AE targeted biopsy (TBx) strategy could reduce the number of follow-up biopsies by omitting TRUS-Bx in the absence of suspicious lesions (one third of men on AS) and potentially even MRITBx in the absence of radiological progression of a known lesion [6] [7] [8] . However, little is known of the performance of MRI AE TBx during follow-up after the confirmatory biopsy. It can be hypothesised that the high-grade (Gleason score ≥3 + 4) prostate cancer detection rate of MRI AE TBx is low at surveillance biopsy, as a significant proportion of men have already been reclassified based on the confirmatory biopsy [2] . In addition, MRI AE TBx is known to miss high-grade prostate cancer detected by TRUS-Bx in 4-14% of men at confirmatory biopsy [6, [9] [10] [11] [12] [13] [14] [15] [16] .
In the present study, we aimed to assess the percentage of men with Gleason score upgrading (≥3 + 4) based on the outcome of MRI AE TBx in our prospective cohort of men on AS who received their first MRI at baseline 3 months after diagnosis, at time of the confirmatory (first repeat) biopsy or at surveillance biopsy after one or more prior repeat biopsies. Furthermore, we stratified biopsy outcomes for the overall Prostate Imaging Reporting and Data System (PI-RADS) score and PSA density (PSA-D), known predictors of Gleason score upgrading, with the aim to selectively identify those men that may not benefit from MRI-TBx and/or additional TRUS-Bx.
Patients and Methods
From November 2013 until November 2016 a total of 216 consecutive men on AS for low-grade (Gleason score 3 + 3) prostate cancer received a first multi-parametric MRI (mp-MRI) AE TBx at our tertiary referral centre. On request of the referring urologist the mp-MRI AE TBx could be combined with an additional TRUS-Bx. A total of six of the 216 men were excluded in the present study, as they had a positive MRI but did not receive MRI-TBx. The remaining 210 men were included in the present study, as the only exclusion criterion was the presence of high-grade (Gleason score ≥3 + 4) prostate cancer. A total of 111/210 (53%) men were participants of the Prostate cancer Research International: Active Surveillance (PRIAS) study (www.prias-project.org), an international web-based AS study with strict criteria for inclusion at diagnosis (Gleason score 3 + 3, T-stage ≤cT2C, PSA level ≤10 ng/mL, two or less positive cores, PSA-D <0.2 ng/mL 2 ) and follow-up [17] . Within the MRI-PRIAS side study an MRI AE TBx is performed at baseline 3 months after diagnosis and during every repeat TRUS-Bx scheduled at 1, 4, 7, and 10 years after diagnosis (Fig. 1) . Inclusion in the MRI-PRIAS side study is however also possible after one or more repeat TRUS-Bx. The only reclassification criterion in the MRI-PRIAS side study is the presence of high-grade prostate cancer at repeat (TBx) biopsy. The remaining 99/210 (47%) men in the present study had low-grade prostate cancer but were followed-up outside of the PRIAS protocol, as they did not meet the strict PRIAS inclusion criteria (PSA level >10 ng/mL and/or two or more positive TRUS-Bx cores) or were referred from a centre not participating in the PRIAS study. All relevant data were included in our prospective, Institutional Review Board-approved database.
mp-MRI
The institutional mp-MRI protocol included: T2-weighted imaging (T2WI), dynamic contrast-enhanced (DCE) imaging and diffusion-weighted imaging (DWI) with apparent diffusion coefficient reconstructions, as previously described [18] , according to the PI-RADS version 2 guidelines [19] . mp-MRI was performed on a 3-T system (Discovery MR750, General Electric Healthcare, Chicago, IL, USA) using a 32-channel pelvic phased-array coil. All MRIs were reviewed by one urogenital radiologist (I.G.S.) with >4 years of prostate MRI experience at the start of this study. Individual lesions were scored according to the PI-RADS (version 2) 5-point likelihood scale for significant prostate cancer [19] . The MRIs were classified as positive in cases of one or more PI-RADS score ≥3 lesions.
MRI-targeted Biopsy
All men with a positive mp-MRI received MRI-TBx. The MRI-TRUS fusion technique was used (UroStation TM , Koelis, Meylan, France) to perform MRI-TBx of all suspicious lesions. MRI lesions were targeted with two to four cores. An additional TRUS-Bx (eight to 12 cores) was performed in all men at confirmatory biopsy and in a subset of men at surveillance biopsy on request of the referring urologist. The biopsy procedures were performed by three operators (A.R.A., F-J.H.D, L.P.B.) who had managed~50 cases at the beginning of this study.
Pathological Review of Biopsy Specimens
One expert uro-pathologist (G.J. V-L.) reviewed all biopsy specimens according to the International Society of Urological Pathology (ISUP) 2014 modified Gleason score [20] . Gleason score upgrading was defined as any Gleason score ≥3 + 4 prostate cancer found by MRI AE TBx and/or TRUS-Bx.
Study Design
Men were stratified into three groups according to timing of the MRI using the MRI-PRIAS follow-up scheme (Fig. 1) ; i.e. MRI at baseline 3 months after diagnosis (Group A), at confirmatory TRUS-Bx 1 year after diagnosis (Group B) or at surveillance biopsy after one or more prior repeat TRUS-Bx 
Statistical Analysis
Statistically significant differences in continuous patient characteristics at time of diagnosis and at time of MRI were assessed with the Kruskal-Wallis test, whilst the chi-squared test for trend was used to test for differences in categorical patient characteristics and the Gleason score upgrading rates between groups (A, B and C). In accordance with the Standards of reporting for MRI-targeted biopsy studies (START) recommendations cross tabulation of biopsy outcomes was performed in the subgroup of men in groups B + C who received additional TRUS-Bx to compare the percentage of Gleason score upgrading detected by MRI AE TBx vs TRUS-Bx [21] . MRI-TBx and TRUS-Bx outcomes were stratified for the overall PI-RADS score and PSA-D as these parameters are known to be strong predictors of Gleason score upgrading [22] [23] [24] . The previously described PSA-D threshold of 0.15 ng/mL 2 was used for stratification [24] [25] [26] [27] . Histograms of the stratified biopsy outcomes were constructed to visualise in which subgroup of men Gleason score upgrading did not occur. The PSA-D was calculated using the MRI-measured prostate volume. The MRI-measured volume was calculated using the prolate ellipsoid formula (length 9 width 9 height 9 p/6). Statistical tests were two-sided with the criterion of significance set at P < 0.05. Statistical analyses were performed with Statistical Package for the Social Sciences (SPSS 
Results

Patient Characteristics at Prostate Cancer Diagnosis and at Time of MRI
In all, 210 men on AS for Gleason score 3 + 3 prostate cancer received a first MRI in our institution. The median [interquartile range (IQR)] age and median (IQR) PSA level at diagnosis of Gleason score 3 + 3 prostate cancer were respectively 65 (60-70) years and 7.0 (5.2-9.6) ng/mL (Table 1) . A total of 37/210 (18%) men had more than two positive TRUS-Bx cores at diagnosis. A total of 97/210 (46%) men received MRI at baseline (Group A), while 39/210 (19%) men received their first MRI at confirmatory biopsy (Group B) and 74/210 (35%) men at surveillance biopsy (Group C). The percentage of men with only one positive TRUSBx core at diagnosis was significantly higher in Group C (65%) as compared to Group A (45%) and Group B (46%). Other patient characteristics at diagnosis did not significantly differ between the groups. At the time of the first MRI, men in Group C had a significantly higher median PSA level (9.5 ng/mL) as compared to men in Group A (7.7 ng/mL) and Group B (7.1 ng/mL). Men in Group B tended to have a lower median PSA-D (0.13 ng/mL 2 ) as compared to men in Group A (0.18 ng/mL 2 ) and Group C (0.17 ng/mL 2 ) ( Table 2) .
Percentage of Gleason Score Upgrading According to the Timing of the MRI
A total of 134/210 (64%) men had a positive MRI and 51/210 (24%) men were upgraded to Gleason score ≥3 + 4 prostate cancer based on MRI-TBx (Table 3 ). The percentage of Gleason score upgrading based on MRI-TBx was similar in Group A (23%, 22/97), Group B (23%, 9/39) and Group C (27%, 20/74). The percentage of Gleason score ≥4 + 3 found by MRI-TBx was significantly higher in Group C (15%, 11/74) as compared to in Group A (3%, 3/97) and Group B (3%, 1/39). The high-grade tumour was located in the peripheral zone in 39/51 (76%) Gleason score-upgraded men and in the transitional zone in 11/ 51 (22%) upgraded men, while one man had high-grade prostate cancer in both posterior and anterior MRI-TBx. 
Identification of a Subgroup of Men Who May not Benefit from MRI-Targeted Biopsy
Identification of a Subgroup of Men Who May not Benefit from TRUS-guided Systematic Biopsy
Additional Gleason score upgrading (not detected by MRITBx) occurred in three of 39 (8%) men who received TRUSBx at confirmatory biopsy and one of 17 (6%) men who received TRUS-Bx at surveillance biopsy. The cross tabulation of MRI AE TBx outcomes vs TRUS-Bx outcomes in men in Group B + C is shown in Table 4 . The percentage of Gleason score ≥3 + 4 prostate cancer detected by MRI AE TBx (79%, 15/19) and TRUS-Bx (74%, 14/19) was comparable. In all 10 men who were upgraded based on both MRI-TBx and TRUSBx positive cores for high-grade prostate cancer of both biopsy approaches were located in the same quadrant of the peripheral zone. Figure 3 
Discussion
Repeated TRUS-Bx in men on AS are often considered burdening, causing a drastic decline in biopsy compliance with longer follow-up [3, 4] . However, compliance with follow-up testing is needed for the detection of initially missed high-grade prostate cancer that has the potential to metastasise. Therefore, strategies are needed to reduce unnecessary biopsies and select only those men who need a repeat biopsy. MRI is increasingly implemented in men on AS and an MRI AE TBx strategy omitting repeat TRUS-Bx could reduce both the number of follow-up biopsies, as well as the number of cores per biopsy procedure. However, MRI AE TBx is known to miss high-grade prostate cancer detected by TRUS-Bx at confirmatory biopsy [6, [9] [10] [11] [12] [13] [14] [15] [16] . Moreover, a recent study showed a significantly lower percentage of Gleason score upgrading based on MRI AE TBx as compared to TRUS-Bx in a cohort of 103 men at surveillance biopsy [28] . In contrast, we surprisingly showed a similar percentage of Gleason score upgrading based on MRI AE TBx after one or more repeat biopsies (27%; group C) as compared to at baseline (23%; group A) and confirmatory biopsy (23%; group B). MRI AE TBx missed high-grade prostate cancer detected by TRUS-Bx in three of 39 (8%) men at confirmatory and one of 17 (6%) men at surveillance biopsy.
The stable percentage of Gleason score upgrading at different time points in our present study is consistent with the stable percentage of reclassification (6 ¼Gleason score upgrading) of~25% found at each repeat TRUS-Bx in the PRIAS study [2] . The slightly higher percentage of Gleason score ≥3 + 4 prostate cancer (27%) and significantly higher percentage of Gleason score ≥4 + 3 (15%) in MRI-TBx in Group C as compared to in Groups A and B could be due to (selection for MRI of men with) a higher risk of upgrading, translated by a higher median PSA-D. Consistent with our present study, several studies have reported MRI AE TBx missing high-grade prostate cancer in 4-9% of men on AS [6, [11] [12] [13] [14] [15] [16] . Two recent studies using an extended 14-core TRUS-Bx scheme even reported a percentage of 12-14% of men in whom MRI AE TBx missed high-grade prostate cancer [9, 10] . A follow-up strategy with only MRI AE TBx thus inevitably misses high-grade prostate cancer detected by TRUS-Bx. The question is whether the benefit of a reduction of one third of follow-up biopsy procedures and a significant reduction of cores per procedure outweighs the harm of missing a high-grade prostate cancer in 4-14% of men at a specific time point during follow-up on AS. Answering this question one has to keep in mind that these missed high-grade prostate cancers might be detected later on during follow-up without missing the window of curability [29] . Furthermore, one has to consider that the previously reported excellent long-term disease-specific survival of men on AS is based on follow-up with TRUS-Bx only [1] . This long-term disease-specific survival is not expected to be worse with an MRI AE TBx strategy, as the previously reported sensitivity of MRI AE TBx for high-grade prostate cancer (71-89%) is at least equal to the sensitivity of TRUS-Bx (63-76%) [6, 9, [14] [15] [16] .
Although MRI seems to be helpful in patient selection for repeat biopsy, solely implementing an MRI AE TBx follow-up strategy does not seem to be sufficient, as high-grade prostate cancer would be missed and two thirds of men would still need to be biopsied. Recently, two robust models for the prediction of Gleason score upgrading at repeat TRUS-Bx were presented based on large datasets of men on AS who did not receive MRI [30, 31] . A multivariable risk-based approach in the presence of MRI seems the way forward to reduce unnecessary biopsies [18] . Walton Diaz et al. [32] [33, 34] . More recently, it was shown that PSA-D remains a strong predictor for Gleason score upgrading when combined with the PI-RADS score in men on AS who received MRI [22] [23] [24] . After stratification for the overall PI-RADS score and PSA-D, using the previously described threshold of 0.15 ng/mL 2 [24] [25] [26] [27] , no Gleason score upgrading was found based on MRI-TBx in men with a PI-RADS score of 3 and a PSA-D of <0.15 ng/mL 2 , nor at additional TRUS-Bx in men with PI-RADS scores of 1-3 and a PSA-D of <0.15 ng/mL 2 . Consistent with our present findings Washino et al. [27] showed no Gleason score upgrading based on MRI-TBx + TRUS-Bx in biopsy na€ ıve men with PIRADS scores of 1-3 and a PSA-D of <0.15 ng/ mL 2 . This suggests that men on AS with PI-RADS scores of 1-3 and a PSA-D of <0.15 ng/mL 2 may not benefit from a follow-up biopsy. Obviously, the percentage of avoided biopsy procedures by omitting repeat biopsy in these men depends on the characteristics of the AS cohort. In our present cohort, 49% (37/76) of men with PI-RADS scores of 1-2 and 44% (15/34) of men with PI-RADS score 3 had a PSA-D of <0.15 ng/mL 2 . Hopefully, a robust prediction model incorporating PI-RADS and PSA-D will be available in the near future to enable risk-based patient selection for repeat biopsy rather than simply stratifying patients based on these clinical parameters. Such a prediction model could be built from the large dataset of the Movember Global Action Plan 3 (GAP3) project [35] .
While the risk of developing metastasis and prostate cancer death is significantly higher in men on AS with Gleason score 3 + 4 as compared to Gleason score 3 + 3 prostate cancer, men with Gleason score 4 + 3 have the highest risk of clinical progression with longer follow-up [36] . Therefore, AS in men with Gleason score ≥3 + 4 prostate cancer cannot be considered the standard of care yet [37] . As in most other institutions, patients in our institution with Gleason score ≥3 + 4 prostate cancer are generally not enrolled in an AS programme and the finding of upgrading to any Gleason score ≥3 + 4 during follow-up usually means switching to active treatment with curative intent. Nevertheless, the high Gleason score upgrading and/or reclassification rates of men on AS trigger the need to extend AS inclusion and follow-up criteria and (limited) Gleason score 3 + 4 disease is nowadays considered suitable for AS by some. In the near future, selection of men with Gleason score 3 + 4 prostate cancer for AS could be based on the prognostic predictors of clinical disease progression cribriform and/or intraductal carcinoma growth and the percentage of grade 4 disease [20, 38, 39] .
A major strength of the present study is that it represents the true clinical setting. Men in our present prospective cohort were referred from eight different peripheral institutions and did not all fulfil the strict inclusion criteria of the PRIAS study (www.prias-project.org). Our present study is mainly limited by the fact that only a subgroup of men at surveillance biopsy received an additional TRUS-Bx along with the MRI AE TBx (17/74, 23%), making it hard to draw conclusions from the comparison between both biopsy strategies. However, our present findings from this comparison were consistent with several previous studies. Furthermore, all men who received a first MRI were included in our study, regardless of time since diagnosis of low-grade prostate cancer. The percentages of Gleason score upgrading based on MRI AE TBx could be different in men who have received a previous MRI AE TBx [22, 23] . Finally, mp-MRI used in the present study, consisting of T2WI, DWI and DCE imaging is not yet widely available. Bi-parametric MRI (T2WI +DWI) is more feasible and less expensive and could therefore help to widely implement MRI in men on AS. Within PI-RADS version 2 the DCE images are used to differentiate between PI-RADS 3 or 4 lesions in the peripheral zone [19] . Only four of 71 (6%) men in the present study with an overall PI-RADS score of 4 would have been classified as having a suspicion score of 3 based on biparametric MRI, three of whom had high-grade prostate cancer in MRI-TBx. However, as all four men had a PSA-D of ≥0.15 ng/mL 2 , the conclusion of the present study (i.e. MRI-TBx may be avoided in men with a PI-RADS score of 3 and a PSA-D of <0.15 ng/mL 2 ) remains unchanged with the use of bi-parametric MRI.
In conclusion, at least one out of five men with Gleason score 3 + 3 prostate cancer at diagnostic TRUS-Bx in our present cohort had Gleason score upgrading based on first MRI AE TBx at baseline, confirmatory or surveillance biopsy. Men with PI-RADS scores of 1-3 and a PSA-D of <0.15 ng/mL 2 did not have Gleason score upgrading at MRI AE TBx or TRUS-Bx at each time point of surveillance. Therefore, riskstratification based on PI-RADS and PSA-D may reduce unnecessary follow-up biopsy procedures in men on AS.
